Navigation Links
Discovery of a novel mechanism for the development of colon cancer
Date:5/5/2008

Recent work from the Finnish Academy Center of Excellence on Cancer Biology at the University of Helsinki, Finland, has shed light on the mechanisms of colon tumor development and may help to design better treatment for this disease.

Colon cancer is one of the most common malignancies in Western countries: both men and women face a lifetime risk of nearly 6% for the development of invasive colorectal cancer. Epidemiologic studies have shown that several factors contribute to the development of this disease, such as high fat, red-meat diet, obesity and lack of vegetables and fibre in the diet.

In the great majority of cases, colorectal cancer arises from an initially benign overgrowth of colonic lining, a so-called adenomatous polyp (Fig. 1), which acquires with time harmful mutations and transforms into a dangerous colonic carcinoma. Observational studies suggest that the adenoma-to-carcinoma sequence takes up to 10 years. Although nearly half of Western population may harbor adenomatous polyps by the age of 50, it is estimated that only a few percent of adenomas will progress to cancer.

The study published as an advance online publication of Cancer Cell, describe a mechanism by which harmless colon polyps acquire the ability to form malignant tumors. Researchers from the University of Helsinki discovered that PROX1, a protein that in embryos controls formation of normal organs, such as liver or eye, becomes abnormally overproduced at early stages of carcinoma development. PROX1 allows tumor cells to grow even in the absence of stimulating signals from surrounding normal tissues, which leads to dangerous overgrowth and development of advanced tumors.

Removal of PROX1 from cancer cells reverses their malignant behaviour, suggesting that PROX1 is a promising target for the development of future therapies for colon cancer.


'/>"/>

Contact: Kari Alitalo
kari.alitalo@helsinki.fi
358-505-003-572
University of Helsinki
Source:Eurekalert

Page: 1

Related medicine news :

1. Investigators unveil new drug discovery tool for Alzheimers disease
2. Discovery to hasten new malaria treatments, vaccines for children
3. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
4. World-first discovery could help treat life-threatening tumors
5. St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia
6. St. Jude discovery offers new avenues to understanding an aggressive form of leukemia
7. Jefferson scientists discovery may help explain smoking-pancreatic cancer link
8. Pollin Pediatric Research Prize awarded for discovery of lifesaving treatment of RDS
9. Mitosis gets harder thanks to new gene discovery
10. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
11. GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Effective today, the wellness ... Highmark Blue Cross Blue Shield Insurance. Owned by ... Nourish Nutrition and Health opened for business earlier ... Wexford. , The basis of the services ... informing clients on the simplicity of leading a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 A ... business and technology startups is now available from ... marketing agency based in the Chicago region. The ... software and information technology (IT), services, ecommerce, healthcare, ... , Marketing disciplines critical to startup success include ...
(Date:7/30/2014)... Printing whole new organs for transplants sounds like something ... technology could one day make actual kidneys, livers, hearts ... In the ACS journal Langmuir , scientists are ... that takes them a step closer to realizing their ... , Yong Huang and colleagues note that this idea ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The 3D ... seen and touched in our new 50,000 square foot ... (just behind Target). , Projectorscreenstore.com is one of the ... range of sophisticated technology and Audio/Visual products for education, ... with Makerbot, the leading manufacturer of 3D printers for ...
(Date:7/30/2014)... July 30, 2014 The Hearing Aid ... five years to 2014. Following a multiyear drop during ... demographic trends, the expansion of private healthcare coverage and, ... that Hearing Aid Clinics industry revenue will ... billion during the five years to 2014. , According ...
Breaking Medicine News(10 mins):Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3
... in the topoisomerase II alpha ( TOP2A ) gene ... compared with non-anthracycline-based regimens, according to a study in ... of the National Cancer Institute. The increased responsiveness ... tumors carry an amplification of the HER 2 ...
... Health & Science University Knight Cancer Institute will evaluate ... Seattle, Wash.) is as effective in delivering highly precise ... it has been in those with prostate cancer. , ... for prostate cancer, and it is our hope to ...
... Senior Living, Inc. (NYSE: SRZ ) today ... its Bank Credit Facility, which eliminates all financial covenants, ... 2009 maturity date."We are very pleased that our bank ... through its maturity date," said Mark Ordan, Sunrise,s chief ...
... NSAIDs can cause liver or stomach illness in ... (HealthDay News) -- Many over-the-counter painkillers and fever ... the potential danger of liver damage and stomach ... will have to include these warnings on all ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... Smithfield Foods, Inc. (NYSE: SFD ) ... no clinical signs or symptoms of the presence of ... its employees at its joint ventures in Mexico. As ... officials and are submitting samples from their swine herds ...
Cached Medicine News:Health News:Gene alterations associated with response to anthracycline therapy for breast cancer 2Health News:OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 3Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 4Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Smithfield Foods Says North American Influenza Not Present in Any of Its Worldwide Operations and Pork is Safe to Eat 2
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), a ... cannabis testing and education markets, announced today that has ... not previously disclosed or, to its knowledge, any other ... "We have noticed unusual price and volume ... days," said Steve Barbee , CEO of DigiPath. ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... FDA approved Makena (hydroxyprogesterone caproate) in February 2011 ... births in women who have had at least one ... approved, a version of the active ingredient of Makena ... drug from a pharmacist who compounded the drug.  In ...
... N.J., Nov. 8, 2011 Covance Inc. (NYSE: ... Credit Suisse Healthcare Conference on Thursday, November 10, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
Medicine Products: